Edwards lifesciences reports third quarter results

Irvine, calif.--(business wire)--edwards lifesciences (nyse: ew) today reported financial results for the quarter ended sept. 30, 2024. highlights and outlook q3 sales from continuing operations grew 9%; constant currency1 sales grew 10% q3 tavr sales grew 6%; constant currency1 sales grew 7% tmtt sales grew 73%; pascal and evoque commercial launches continue to progress well q3 eps of $5.13; adjusted1 eps of $0.67 completed sale of critical care in q3, resulting in significant one-time gain pi.
EW Ratings Summary
EW Quant Ranking